NSI-566 is an experimental stem cell-based therapy that Seneca Biopharma (previously known as Neuralstem) is developing as a potential treatment for amyotrophic lateral sclerosis (ALS). The company also is investigating NSI-566 as a potential treatment for chronic spinal cord injury and to restore motor deficits…
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder in which nerve cells that control muscles gradually degrade. With disease progression, more and more muscles are affected, and it becomes challenging for patients to accomplish everyday tasks. The goal of occupational therapy is to help patients maintain their…
Amyotrophic lateral sclerosis (ALS) is a disease that leads to the progressive degeneration of nerve cells. Most patients experience some disability as a result of the disease and have difficulty with daily tasks like walking, feeding, and dressing. While there is no cure for ALS yet, there are a…
Amyotrophic lateral sclerosis (ALS) is a serious disorder that causes progressive loss of motor neurons, the nerve cells that control muscle movement. Most patients will experience some disability, including difficulty swallowing and slurred speech, as a result of the loss of these nerve cells. What is speech therapy? Speech therapy…
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder associated with the death of motor neurons. These are nerve cells that control the voluntary muscles, which are essential for movement. As the condition progresses, the muscles weaken and waste away, resulting in a loss of muscle control. Although ALS…
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects the nerves that control muscle function. The disease leads to muscle weakness, including the muscles needed for breathing. This can be very serious, with respiratory failure being the primary cause of death in ALS patients. Supporting breathing…
About four years ago, ALS impeded my speaking ability. Like more than 80 percent of all ALS patients, I now have dysarthria, or what I refer to as my “ALS voice.” It’s a slurred, slow speech pattern with a nasal tone and imprecise pronunciation of consonants. For…
The U.S. Food and Drug Administration (FDA) has accepted for review the new drug application (NDA) of Biohaven Pharmaceuticals’ BHV-0223, a sublingual (dissolved under the tongue) form of riluzole, as a treatment for amyotrophic lateral sclerosis (ALS). Biohaven has begun enrollment of ALS patients for its Phase 2/3…
The brain’s waste clearance pathway, known as the glymphatic system, could enable more efficient delivery of therapeutics into the brain for the treatment of disorders such as amyotrophic lateral sclerosis (ALS), Alzheimer’s, Parkinson’s, and brain cancer, according to a study. The study, “Transcranial optical…
Before ALS, whenever I thought about the future, I assumed my life would continue in a state of health and happiness, filled with lots of interesting activities. But in 2010, when I learned I had ALS, thinking about my future became very dismal and frightening. My mind…
